Literature DB >> 25256646

A novel open-source drug-delivery system that allows for first-of-kind simulation of nonadherence to pharmacological interventions in animal disease models.

Kyle E Thomson1, H Steve White2.   

Abstract

BACKGROUND: Nonadherence to a physician-prescribed therapeutic intervention is a costly, dangerous, and sometimes fatal concern in healthcare. To date, the study of nonadherence has been constrained to clinical studies. The novel approach described herein allows for the preclinical study of nonadherence in etiologically relevant disease animal model systems. NEW
METHOD: The method herein describes a novel computer-automated pellet delivery system which allows for the study of nonadherence in animals. This system described herein allows for tight experimenter control of treatment using a drug-in-food protocol. Food-restricted animals receive either medicated or unmedicated pellets, designed to mimic either "taking" or "missing" a drug.
RESULTS: The system described permits the distribution of medicated or unmedicated food pellets on an experimenter-defined feeding schedule. The flexibility of this system permits the delivery of drug according to the known pharmacokinetics of investigational drugs. COMPARISON WITH OTHER
METHODS: Current clinical adherence research relies on medication-event monitoring system (MEMS) tracking caps, which allows clinicians to directly monitor patient adherence. However, correlating the effects of nonadherence to efficacy still relies on the accuracy of patient journals.
CONCLUSION: This system allows for the design of studies to address the impact of nonadherence in an etiologically relevant animal model. Given methodological and ethical concerns of designing clinical studies of nonadherence, animal studies are critical to better understand medication adherence. While the system described was designed to measure the impact of nonadherence on seizure control, it is clear that the utility of this system extends beyond epilepsy to include other disease states.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-seizure drug; Chronic drug delivery; Drug discovery; Epilepsy; Nonadherence; Noncompliance

Mesh:

Substances:

Year:  2014        PMID: 25256646      PMCID: PMC4363129          DOI: 10.1016/j.jneumeth.2014.09.019

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  18 in total

1.  The price you pay for the drug not taken.

Authors:  R McCarthy
Journal:  Bus Health       Date:  1998-10

Review 2.  Forced swimming test in mice: a review of antidepressant activity.

Authors:  Benoit Petit-Demouliere; Franck Chenu; Michel Bourin
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

Review 3.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

Review 4.  Adherence to antiepilepsy drug therapy.

Authors:  Edward Faught
Journal:  Epilepsy Behav       Date:  2012-10-23       Impact factor: 2.937

Review 5.  The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice.

Authors:  John F Cryan; Cedric Mombereau; Annick Vassout
Journal:  Neurosci Biobehav Rev       Date:  2005       Impact factor: 8.989

6.  Anticonvulsant effects of carbamazepine on spontaneous seizures in rats with kainate-induced epilepsy: comparison of intraperitoneal injections with drug-in-food protocols.

Authors:  Heidi L Grabenstatter; Suzanne Clark; F Edward Dudek
Journal:  Epilepsia       Date:  2007-08-17       Impact factor: 5.864

7.  Early pediatric antiepileptic drug nonadherence is related to lower long-term seizure freedom.

Authors:  Avani C Modi; Joseph R Rausch; Tracy A Glauser
Journal:  Neurology       Date:  2014-01-24       Impact factor: 9.910

8.  Antidepressants, depression and suicide: an analysis of the San Diego study.

Authors:  G Isacsson; U Bergman; C L Rich
Journal:  J Affect Disord       Date:  1994-12       Impact factor: 4.839

9.  Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease.

Authors:  Debby Van Dam; Katrien Coen; Peter Paul De Deyn
Journal:  Psychopharmacology (Berl)       Date:  2007-11-16       Impact factor: 4.530

10.  Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study.

Authors:  Tracy R Glass; Manuel Battegay; Matthias Cavassini; Sabina De Geest; Hansjakob Furrer; Pietro L Vernazza; Bernard Hirschel; Enos Bernasconi; Martin Rickenbach; Huldrych F Günthard; Heiner C Bucher
Journal:  J Acquir Immune Defic Syndr       Date:  2010-06       Impact factor: 3.731

View more
  12 in total

1.  Conditional Knock-out of mGluR5 from Astrocytes during Epilepsy Development Impairs High-Frequency Glutamate Uptake.

Authors:  Anthony D Umpierre; Peter J West; John A White; Karen S Wilcox
Journal:  J Neurosci       Date:  2018-11-30       Impact factor: 6.167

Review 2.  Disease modification in epilepsy: from animal models to clinical applications.

Authors:  Melissa L Barker-Haliski; Dan Friedman; Jacqueline A French; H Steve White
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

3.  Ultrastructural and functional changes at the tripartite synapse during epileptogenesis in a model of temporal lobe epilepsy.

Authors:  Cheryl Clarkson; Roy M Smeal; Meredith G Hasenoehrl; John A White; Maria E Rubio; Karen S Wilcox
Journal:  Exp Neurol       Date:  2020-01-11       Impact factor: 5.330

4.  Repeated low-dose kainate administration in C57BL/6J mice produces temporal lobe epilepsy pathology but infrequent spontaneous seizures.

Authors:  Anthony D Umpierre; Isaiah V Bennett; Lismore D Nebeker; Thomas G Newell; Bruce B Tian; Kyle E Thomson; H Steve White; John A White; Karen S Wilcox
Journal:  Exp Neurol       Date:  2016-02-16       Impact factor: 5.330

Review 5.  Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.

Authors:  Wolfgang Löscher
Journal:  Neurochem Res       Date:  2017-03-13       Impact factor: 3.996

6.  Validation of a Preclinical Drug Screening Platform for Pharmacoresistant Epilepsy.

Authors:  Melissa L Barker-Haliski; Kristina Johnson; Peggy Billingsley; Jennifer Huff; Laura J Handy; Rizvana Khaleel; Zhenmei Lu; Matthew J Mau; Timothy H Pruess; Carlos Rueda; Gerald Saunders; Tristan K Underwood; Fabiola Vanegas; Misty D Smith; Peter J West; Karen S Wilcox
Journal:  Neurochem Res       Date:  2017-03-16       Impact factor: 3.996

7.  Development of an antiepileptogenesis drug screening platform: Effects of everolimus and phenobarbital.

Authors:  Melissa Barker-Haliski; Kevin Knox; Dannielle Zierath; Zachery Koneval; Cameron Metcalf; Karen S Wilcox; H Steve White
Journal:  Epilepsia       Date:  2021-06-02       Impact factor: 6.740

8.  Hippocampal TNFα Signaling Contributes to Seizure Generation in an Infection-Induced Mouse Model of Limbic Epilepsy.

Authors:  Dipan C Patel; Glenna Wallis; E Jill Dahle; Pallavi B McElroy; Kyle E Thomson; Raymond J Tesi; David E Szymkowski; Peter J West; Roy M Smeal; Manisha Patel; Robert S Fujinami; H Steve White; Karen S Wilcox
Journal:  eNeuro       Date:  2017-05-09

9.  Accurate detection of spontaneous seizures using a generalized linear model with external validation.

Authors:  Nicolas F Fumeaux; Senan Ebrahim; Brian F Coughlin; Adesh Kadambi; Aafreen Azmi; Jen X Xu; Maurice Abou Jaoude; Sunil B Nagaraj; Kyle E Thomson; Thomas G Newell; Cameron S Metcalf; Karen S Wilcox; Eyal Y Kimchi; Marcio F D Moraes; Sydney S Cash
Journal:  Epilepsia       Date:  2020-08-06       Impact factor: 6.740

10.  Monitoring Heritage Buildings with Open Source Hardware Sensors: A Case Study of the Mosque-Cathedral of Córdoba.

Authors:  Francisco Javier Mesas-Carrascosa; Daniel Verdú Santano; Jose Emilio Meroño de Larriva; Rafael Ortíz Cordero; Rafael Enrique Hidalgo Fernández; Alfonso García-Ferrer
Journal:  Sensors (Basel)       Date:  2016-09-29       Impact factor: 3.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.